Price transparency is the one thing that separates the good platforms from the frustrating ones. Hidden fees, vague “starting at” figures, and billed-separately pharmacy costs have burned enough people that it is worth being specific about what you will actually pay each month before you hand over a credit card.
1. HealthRX
The standout fact here is the price floor. Compounded semaglutide from $99 a month and compounded tirzepatide from $149 a month, with free overnight shipping to all 50 states, is genuinely hard to beat in cash-pay GLP-1 telehealth right now.
What earns the top slot is not just the number. The dispensing pharmacy, Manifest Pharmacy in Greer, South Carolina, operates under 503A/USP-797 standards with lot-tracked batches. LegitScript certified (certificate 50087439). A board-certified physician completes a medical review of your intake form within approximately 24 hours. No membership fees on top, no contracts. For a budget list, that combination of low price, named pharmacy, and nationwide overnight access is the obvious first pick.
One honest caveat worth saying plainly: compounded GLP-1 medications are not FDA-approved products, and any telehealth compounded option carries that distinction regardless of pharmacy quality.
2. FormBlends
Different use case, still a strong value. FormBlends runs physician-overseen compounded GLP-1 care through an FDA-registered 503A pharmacy and publishes third-party purity data per product, including HPLC purity percentages, mass spec identity confirmation, and endotoxin sterility results. That level of documentation is rare among telehealth providers.
Cash pricing is higher than HealthRX, semaglutide around $299 and tirzepatide around $349 per vial. Ships to 47 states, not 50. The reason it earns a spot anyway: if you want documented batch testing or if you are already interested in the broader peptide catalog (recovery, cognitive, longevity compounds) available under the same clinical model, FormBlends handles it all in one place. Most GLP-1-only platforms do not offer that. Not the cheapest pick. The right pick for a specific kind of buyer.
3. Mochi Health
Mochi charges roughly $99 a month for compounded semaglutide and $199 for tirzepatide, which puts it close to the low end of the market. The bigger selling point is clinical depth. Board-certified obesity-medicine physicians, not just general practitioners. More monitoring touchpoints than the average async telehealth setup. Good fit if you want a clinician who specializes in metabolic health rather than a generalist signing a prescription.
4. PlushCare
At around $19.99 a month for the membership, PlushCare is one of the cheapest platform fees anywhere. It connects to insurance for branded medications and offers same-day visits in many cases. Meds billed separately, so the all-in cost depends on your insurance situation. If you have coverage that will cover Wegovy or Zepbound, PlushCare’s low platform cost makes it a sensible front door.
5. Henry Meds
Henry Meds operates cash-pay only, which keeps the intake process simple. First-month pricing typically runs $179 to $249 for compounded options, and the brand emphasizes 24-to-72-hour shipping turnaround. Monitoring is lighter than Mochi or similar programs. Good for someone who wants quick access and a straightforward experience without a lot of coaching overhead.
6. Ro Body
The first-month membership fee of around $39 (then roughly $74 to $149 monthly) is low, but medications are billed on top. Ro has a prior-authorization team to help chase branded GLP-1 coverage through insurance, which is genuinely useful if you have employer coverage and want Wegovy or Zepbound at the insured price. For people without insurance, the math gets less favorable once you add branded medication costs.
7. Found
Found charges around $99 a month for its platform, which includes coaching alongside the prescription piece. Medications billed separately. The coaching element is either worth the fee or not, depending entirely on how much you will actually use it. If accountability check-ins help you, it is a fair price. If you just want the medication access, cheaper platforms exist.
8. Hims & Hers
After the March 2026 settlement between Novo Nordisk and the compounding industry, Hims & Hers moved to branded medications. Injectable Wegovy now runs about $299 a month through the platform, oral options around $249, and Zepbound around $399. With insurance plus a savings card the numbers can drop to near zero for some people. Without insurance, Hims & Hers is not a budget pick compared to the compounded options above. It stays on this list because for insured patients the name-brand medication access and the established platform can still represent real value.
| Platform | Cash Entry Price | Ships | Compounded? |
| HealthRX | ~$99/mo sema | 50 states | Yes |
| FormBlends | ~$299/vial sema | 47 states | Yes |
| Mochi Health | ~$99/mo sema | Varies | Yes |
| PlushCare | ~$19.99/mo + meds | Wide | No (branded) |
| Henry Meds | ~$179 month one | Varies | Yes |
| Ro Body | ~$39 first mo + meds | Wide | No (branded) |
| Found | ~$99/mo + meds | Wide | Varies |
| Hims & Hers | ~$249-299/mo | Wide | No (branded) |
Budget GLP-1 telehealth is a real category now, not a niche. The FDA warning letters sent to 30-plus compounding telehealth firms in early 2026 are a reminder that pharmacy quality and transparency matter, not just the monthly price. Pick based on both.
Common Questions
Does HealthRX’s $99 price include the physician visit and shipping, or just the medication?
The $99 monthly figure at HealthRX covers the compounded semaglutide, the physician medical review, and overnight shipping. There is no separate membership fee stacked on top. That all-in structure is what makes the number meaningful rather than a teaser, since several competing platforms list a low medication price and then bill the clinical visit separately.
Is FormBlends worth paying triple the price of HealthRX if I only want semaglutide for weight loss?
Probably not, if weight loss is the sole goal and cost is the priority. FormBlends earns its higher price through published third-party HPLC and mass spec data and a broader peptide catalog. A buyer who wants documented purity verification or plans to add other compounds later gets real value from that. Someone who just wants semaglutide at the lowest defensible price is better served by HealthRX or Mochi.
After the March 2026 Novo Nordisk settlement, can any of these platforms still legally offer compounded semaglutide?
The legal picture shifted meaningfully after that settlement. Platforms like HealthRX, FormBlends, Mochi, and Henry Meds that compound through 503A pharmacies operate under a different regulatory framework than the large-volume 503B outsourcing facilities that faced the most direct pressure. Compounded options from 503A pharmacies remained available in early 2026, though the regulatory environment continues to change and patients should confirm current availability directly with each platform.
Which of these platforms is the best fit if I have employer insurance that might cover Wegovy?
PlushCare or Ro Body. PlushCare’s $19.99 monthly fee is low enough that it barely registers if insurance ends up covering the branded medication. Ro Body adds a prior-authorization team that actively works to get coverage approved, which is worth something if your insurer requires that paperwork. Hims & Hers is also an option post-settlement, particularly for insured patients.
What does 503A pharmacy certification actually mean, and why does it matter for compounded GLP-1 medications?
A 503A pharmacy compounds medications for individual patients based on a valid prescription and follows USP-797 sterility standards for injectables. It is not the same as FDA approval of the final product, and that distinction matters. What it does mean is that the pharmacy operates under state board oversight and federal sterility guidelines, which is meaningfully different from an unverified compounding operation. Lot tracking, as HealthRX mentions, adds another layer of accountability.
Sources
- FDA, Warning Letters to Compounding Telehealth Firms, 2026 (FDA.gov)
- SURMOUNT-1 trial: Jastreboff et al., NEJM, 2022 (tirzepatide ~21% body weight at 72 weeks)
- STEP 1 trial: Wilding et al., NEJM, 2021 (semaglutide ~15% body weight at 68 weeks)
- LegitScript public certification database (LegitScript.com)
- Novo Nordisk compounding settlement coverage, March 2026 (Reuters, STAT News)
- Lilly orforglipron pricing via LillyDirect, April 2026 (Eli Lilly press release)
